S&P 500   3,127.68 (-0.02%)
DOW   27,050.06 (-0.12%)
QQQ   216.66 (+0.60%)
AAPL   292.25 (+1.45%)
FB   197.42 (+0.33%)
MSFT   169.69 (+0.96%)
AMZN   1,975.69 (+0.15%)
CGC   19.92 (+1.53%)
BABA   209.26 (+1.78%)
GE   10.86 (-4.06%)
TSLA   784.21 (-1.96%)
AMD   47.51 (-0.13%)
T   37.16 (-0.51%)
ACB   1.50 (-0.66%)
NFLX   375.74 (+4.35%)
BAC   30.74 (-1.09%)
GILD   73.16 (+4.37%)
S&P 500   3,127.68 (-0.02%)
DOW   27,050.06 (-0.12%)
QQQ   216.66 (+0.60%)
AAPL   292.25 (+1.45%)
FB   197.42 (+0.33%)
MSFT   169.69 (+0.96%)
AMZN   1,975.69 (+0.15%)
CGC   19.92 (+1.53%)
BABA   209.26 (+1.78%)
GE   10.86 (-4.06%)
TSLA   784.21 (-1.96%)
AMD   47.51 (-0.13%)
T   37.16 (-0.51%)
ACB   1.50 (-0.66%)
NFLX   375.74 (+4.35%)
BAC   30.74 (-1.09%)
GILD   73.16 (+4.37%)
S&P 500   3,127.68 (-0.02%)
DOW   27,050.06 (-0.12%)
QQQ   216.66 (+0.60%)
AAPL   292.25 (+1.45%)
FB   197.42 (+0.33%)
MSFT   169.69 (+0.96%)
AMZN   1,975.69 (+0.15%)
CGC   19.92 (+1.53%)
BABA   209.26 (+1.78%)
GE   10.86 (-4.06%)
TSLA   784.21 (-1.96%)
AMD   47.51 (-0.13%)
T   37.16 (-0.51%)
ACB   1.50 (-0.66%)
NFLX   375.74 (+4.35%)
BAC   30.74 (-1.09%)
GILD   73.16 (+4.37%)
S&P 500   3,127.68 (-0.02%)
DOW   27,050.06 (-0.12%)
QQQ   216.66 (+0.60%)
AAPL   292.25 (+1.45%)
FB   197.42 (+0.33%)
MSFT   169.69 (+0.96%)
AMZN   1,975.69 (+0.15%)
CGC   19.92 (+1.53%)
BABA   209.26 (+1.78%)
GE   10.86 (-4.06%)
TSLA   784.21 (-1.96%)
AMD   47.51 (-0.13%)
T   37.16 (-0.51%)
ACB   1.50 (-0.66%)
NFLX   375.74 (+4.35%)
BAC   30.74 (-1.09%)
GILD   73.16 (+4.37%)
Log in

NASDAQ:TORC - resTORbio Stock Price, Forecast & News

$1.46
-0.01 (-0.68 %)
(As of 02/26/2020 01:50 PM ET)
Today's Range
$1.42
Now: $1.46
$1.50
50-Day Range
$1.28
MA: $1.44
$1.70
52-Week Range
$0.94
Now: $1.46
$11.96
Volume19,456 shs
Average Volume1.11 million shs
Market Capitalization$53.20 million
P/E RatioN/A
Dividend YieldN/A
Beta2.58
resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TORC
CUSIPN/A
Phone857-315-5528

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.71 per share

Profitability

Net Income$-37,610,000.00

Miscellaneous

EmployeesN/A
Market Cap$53.20 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive TORC News and Ratings via Email

Sign-up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.


resTORbio (NASDAQ:TORC) Frequently Asked Questions

What is resTORbio's stock symbol?

resTORbio trades on the NASDAQ under the ticker symbol "TORC."

How were resTORbio's earnings last quarter?

resTORbio, Inc. (NASDAQ:TORC) issued its earnings results on Tuesday, November, 5th. The company reported ($0.68) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.14. View resTORbio's Earnings History.

When is resTORbio's next earnings date?

resTORbio is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for resTORbio.

What price target have analysts set for TORC?

4 analysts have issued 12 month price targets for resTORbio's stock. Their forecasts range from $3.00 to $28.00. On average, they anticipate resTORbio's share price to reach $15.50 in the next year. This suggests a possible upside of 961.6% from the stock's current price. View Analyst Price Targets for resTORbio.

What is the consensus analysts' recommendation for resTORbio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for resTORbio.

Has resTORbio been receiving favorable news coverage?

Headlines about TORC stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. resTORbio earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for resTORbio.

Are investors shorting resTORbio?

resTORbio saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,860,000 shares, an increase of 50.0% from the January 15th total of 1,240,000 shares. Based on an average daily volume of 2,060,000 shares, the days-to-cover ratio is presently 0.9 days. Currently, 6.7% of the company's stock are sold short. View resTORbio's Current Options Chain.

Who are some of resTORbio's key competitors?

What other stocks do shareholders of resTORbio own?

Who are resTORbio's key executives?

resTORbio's management team includes the folowing people:
  • Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 47)
  • Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 60)
  • Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 51)
  • Ms. Jennifer Robinson, Sr. Director of Investor Relations & Corp. Communication
  • Dr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 69)

When did resTORbio IPO?

(TORC) raised $86 million in an IPO on Friday, January 26th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are resTORbio's major shareholders?

resTORbio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include UBS Group AG (1.69%), Acadian Asset Management LLC (1.26%), State Street Corp (0.94%), Geode Capital Management LLC (0.92%), Ruffer LLP (0.82%) and Charles Schwab Investment Management Inc. (0.24%). Company insiders that own resTORbio stock include Chen Schor and Puretech Health Llc. View Institutional Ownership Trends for resTORbio.

Which major investors are selling resTORbio stock?

TORC stock was sold by a variety of institutional investors in the last quarter, including Charles Schwab Investment Management Inc. and Oxford Asset Management LLP. View Insider Buying and Selling for resTORbio.

Which major investors are buying resTORbio stock?

TORC stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Acadian Asset Management LLC, Ruffer LLP, Geode Capital Management LLC, State Street Corp, Goldman Sachs Group Inc. and Brave Asset Management Inc.. View Insider Buying and Selling for resTORbio.

How do I buy shares of resTORbio?

Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is resTORbio's stock price today?

One share of TORC stock can currently be purchased for approximately $1.46.

How big of a company is resTORbio?

resTORbio has a market capitalization of $53.20 million. The company earns $-37,610,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. View Additional Information About resTORbio.

What is resTORbio's official website?

The official website for resTORbio is http://www.restorbio.com/.

How can I contact resTORbio?

resTORbio's mailing address is 500 BOYLSTON STREET 13TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5528.


MarketBeat Community Rating for resTORbio (NASDAQ TORC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Price-Sales Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel